nodes	percent_of_prediction	percent_of_DWPC	metapath
Loperamide—CYP2B6—Methimazole—Graves' disease	0.453	0.559	CbGbCtD
Loperamide—CYP2D6—Methimazole—Graves' disease	0.219	0.27	CbGbCtD
Loperamide—CYP3A4—Methimazole—Graves' disease	0.139	0.172	CbGbCtD
Loperamide—POMC—connective tissue—Graves' disease	0.00781	0.142	CbGeAlD
Loperamide—POMC—pituitary gland—Graves' disease	0.00602	0.109	CbGeAlD
Loperamide—POMC—adipose tissue—Graves' disease	0.00599	0.109	CbGeAlD
Loperamide—POMC—thyroid gland—Graves' disease	0.00519	0.0942	CbGeAlD
Loperamide—CALM3—eye—Graves' disease	0.00282	0.0512	CbGeAlD
Loperamide—CALM2—eye—Graves' disease	0.00221	0.0402	CbGeAlD
Loperamide—CALM1—eye—Graves' disease	0.0022	0.04	CbGeAlD
Loperamide—CALM2—connective tissue—Graves' disease	0.00213	0.0387	CbGeAlD
Loperamide—CALM1—connective tissue—Graves' disease	0.00212	0.0385	CbGeAlD
Loperamide—CALM3—pituitary gland—Graves' disease	0.00209	0.038	CbGeAlD
Loperamide—CALM3—adipose tissue—Graves' disease	0.00208	0.0378	CbGeAlD
Loperamide—CALM3—thyroid gland—Graves' disease	0.0018	0.0328	CbGeAlD
Loperamide—CALM2—pituitary gland—Graves' disease	0.00164	0.0298	CbGeAlD
Loperamide—Drowsiness—Methimazole—Graves' disease	0.00164	0.107	CcSEcCtD
Loperamide—CALM2—adipose tissue—Graves' disease	0.00164	0.0297	CbGeAlD
Loperamide—CALM1—pituitary gland—Graves' disease	0.00164	0.0297	CbGeAlD
Loperamide—CALM1—adipose tissue—Graves' disease	0.00163	0.0296	CbGeAlD
Loperamide—CALM2—thyroid gland—Graves' disease	0.00142	0.0257	CbGeAlD
Loperamide—CALM1—thyroid gland—Graves' disease	0.00141	0.0256	CbGeAlD
Loperamide—Drowsiness—Propylthiouracil—Graves' disease	0.0014	0.0906	CcSEcCtD
Loperamide—CYP2C8—pituitary gland—Graves' disease	0.00136	0.0247	CbGeAlD
Loperamide—Somnolence—Methimazole—Graves' disease	0.000931	0.0604	CcSEcCtD
Loperamide—Dyspepsia—Methimazole—Graves' disease	0.000922	0.0598	CcSEcCtD
Loperamide—Urticaria—Methimazole—Graves' disease	0.000832	0.054	CcSEcCtD
Loperamide—Somnolence—Propylthiouracil—Graves' disease	0.000792	0.0514	CcSEcCtD
Loperamide—Dyspepsia—Propylthiouracil—Graves' disease	0.000784	0.0508	CcSEcCtD
Loperamide—Pruritus—Methimazole—Graves' disease	0.000741	0.0481	CcSEcCtD
Loperamide—Urticaria—Propylthiouracil—Graves' disease	0.000708	0.0459	CcSEcCtD
Loperamide—Vomiting—Methimazole—Graves' disease	0.000666	0.0432	CcSEcCtD
Loperamide—Rash—Methimazole—Graves' disease	0.000661	0.0428	CcSEcCtD
Loperamide—Dermatitis—Methimazole—Graves' disease	0.00066	0.0428	CcSEcCtD
Loperamide—Headache—Methimazole—Graves' disease	0.000656	0.0426	CcSEcCtD
Loperamide—ABCB1—pituitary gland—Graves' disease	0.000653	0.0119	CbGeAlD
Loperamide—ABCB1—adipose tissue—Graves' disease	0.00065	0.0118	CbGeAlD
Loperamide—Pruritus—Propylthiouracil—Graves' disease	0.00063	0.0409	CcSEcCtD
Loperamide—Nausea—Methimazole—Graves' disease	0.000622	0.0404	CcSEcCtD
Loperamide—Vomiting—Propylthiouracil—Graves' disease	0.000566	0.0367	CcSEcCtD
Loperamide—ABCB1—thyroid gland—Graves' disease	0.000563	0.0102	CbGeAlD
Loperamide—Rash—Propylthiouracil—Graves' disease	0.000562	0.0364	CcSEcCtD
Loperamide—Dermatitis—Propylthiouracil—Graves' disease	0.000561	0.0364	CcSEcCtD
Loperamide—Headache—Propylthiouracil—Graves' disease	0.000558	0.0362	CcSEcCtD
Loperamide—Nausea—Propylthiouracil—Graves' disease	0.000529	0.0343	CcSEcCtD
Loperamide—ABCB1—Allograft Rejection—CD40—Graves' disease	0.000409	0.00343	CbGpPWpGaD
Loperamide—CALM2—Downstream signaling in naïve CD8+ T cells—HLA-A—Graves' disease	0.000407	0.00342	CbGpPWpGaD
Loperamide—CALM1—Downstream signaling in naïve CD8+ T cells—HLA-A—Graves' disease	0.000407	0.00342	CbGpPWpGaD
Loperamide—ABCB1—Allograft Rejection—CTLA4—Graves' disease	0.000403	0.00338	CbGpPWpGaD
Loperamide—CALM3—Neuronal System—GABRA3—Graves' disease	0.000403	0.00338	CbGpPWpGaD
Loperamide—OPRM1—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.000401	0.00336	CbGpPWpGaD
Loperamide—CALM3—IFN-gamma pathway—IFNG—Graves' disease	0.000396	0.00332	CbGpPWpGaD
Loperamide—CACNA1A—Metabolism—B3GNT2—Graves' disease	0.000393	0.00329	CbGpPWpGaD
Loperamide—CALM1—Neuronal System—GABRA3—Graves' disease	0.00039	0.00327	CbGpPWpGaD
Loperamide—CALM2—Neuronal System—GABRA3—Graves' disease	0.00039	0.00327	CbGpPWpGaD
Loperamide—OPRM1—Peptide ligand-binding receptors—CXCL10—Graves' disease	0.000386	0.00324	CbGpPWpGaD
Loperamide—OPRK1—G alpha (i) signalling events—CXCL10—Graves' disease	0.000386	0.00323	CbGpPWpGaD
Loperamide—CALM2—IFN-gamma pathway—IFNG—Graves' disease	0.000383	0.00321	CbGpPWpGaD
Loperamide—CALM1—IFN-gamma pathway—IFNG—Graves' disease	0.000383	0.00321	CbGpPWpGaD
Loperamide—POMC—GPCR downstream signaling—CXCL10—Graves' disease	0.000379	0.00318	CbGpPWpGaD
Loperamide—CALM3—Alzheimers Disease—FAS—Graves' disease	0.000371	0.00311	CbGpPWpGaD
Loperamide—OPRK1—GPCR ligand binding—TSHR—Graves' disease	0.000361	0.00303	CbGpPWpGaD
Loperamide—CALM2—Alzheimers Disease—FAS—Graves' disease	0.000359	0.00301	CbGpPWpGaD
Loperamide—CALM1—Alzheimers Disease—FAS—Graves' disease	0.000359	0.00301	CbGpPWpGaD
Loperamide—CALM3—IFN-gamma pathway—IL1B—Graves' disease	0.000353	0.00296	CbGpPWpGaD
Loperamide—CALM3—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—Graves' disease	0.000351	0.00294	CbGpPWpGaD
Loperamide—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.00035	0.00293	CbGpPWpGaD
Loperamide—CALM3—Carbohydrate metabolism—B3GNT2—Graves' disease	0.000349	0.00292	CbGpPWpGaD
Loperamide—POMC—Signaling by GPCR—CXCL10—Graves' disease	0.000344	0.00289	CbGpPWpGaD
Loperamide—OPRM1—TCR Signaling Pathway—CD4—Graves' disease	0.000342	0.00287	CbGpPWpGaD
Loperamide—CALM1—IFN-gamma pathway—IL1B—Graves' disease	0.000342	0.00286	CbGpPWpGaD
Loperamide—CALM2—IFN-gamma pathway—IL1B—Graves' disease	0.000342	0.00286	CbGpPWpGaD
Loperamide—CALM1—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—Graves' disease	0.000339	0.00285	CbGpPWpGaD
Loperamide—CALM2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—Graves' disease	0.000339	0.00285	CbGpPWpGaD
Loperamide—CALM2—Carbohydrate metabolism—B3GNT2—Graves' disease	0.000337	0.00283	CbGpPWpGaD
Loperamide—CALM1—Carbohydrate metabolism—B3GNT2—Graves' disease	0.000337	0.00283	CbGpPWpGaD
Loperamide—ABCB1—Allograft Rejection—HLA-DQB1—Graves' disease	0.000332	0.00278	CbGpPWpGaD
Loperamide—OPRM1—G alpha (i) signalling events—CXCL10—Graves' disease	0.000326	0.00273	CbGpPWpGaD
Loperamide—OPRM1—TCR Signaling Pathway—IL1B—Graves' disease	0.000316	0.00265	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—TSHR—Graves' disease	0.000315	0.00264	CbGpPWpGaD
Loperamide—CALM3—DAP12 signaling—HLA-E—Graves' disease	0.000308	0.00258	CbGpPWpGaD
Loperamide—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.000307	0.00257	CbGpPWpGaD
Loperamide—OPRM1—GPCR ligand binding—TSHR—Graves' disease	0.000305	0.00256	CbGpPWpGaD
Loperamide—ABCB1—Allograft Rejection—HLA-B—Graves' disease	0.000298	0.0025	CbGpPWpGaD
Loperamide—CALM1—DAP12 signaling—HLA-E—Graves' disease	0.000298	0.0025	CbGpPWpGaD
Loperamide—CALM2—DAP12 signaling—HLA-E—Graves' disease	0.000298	0.0025	CbGpPWpGaD
Loperamide—ABCB1—Allograft Rejection—FASLG—Graves' disease	0.000292	0.00244	CbGpPWpGaD
Loperamide—POMC—GPCR downstream signaling—IL2RA—Graves' disease	0.00029	0.00243	CbGpPWpGaD
Loperamide—CALM3—DAP12 interactions—HLA-E—Graves' disease	0.00029	0.00243	CbGpPWpGaD
Loperamide—ABCB1—Allograft Rejection—FAS—Graves' disease	0.000281	0.00236	CbGpPWpGaD
Loperamide—CALM3—Downstream signaling in naïve CD8+ T cells—IFNG—Graves' disease	0.000281	0.00236	CbGpPWpGaD
Loperamide—CALM2—DAP12 interactions—HLA-E—Graves' disease	0.00028	0.00235	CbGpPWpGaD
Loperamide—CALM1—DAP12 interactions—HLA-E—Graves' disease	0.00028	0.00235	CbGpPWpGaD
Loperamide—ABCB1—Allograft Rejection—IL2RA—Graves' disease	0.00028	0.00234	CbGpPWpGaD
Loperamide—ABCB1—Allograft Rejection—HLA-A—Graves' disease	0.000276	0.00232	CbGpPWpGaD
Loperamide—CALM2—Downstream signaling in naïve CD8+ T cells—IFNG—Graves' disease	0.000272	0.00228	CbGpPWpGaD
Loperamide—CALM1—Downstream signaling in naïve CD8+ T cells—IFNG—Graves' disease	0.000272	0.00228	CbGpPWpGaD
Loperamide—OPRD1—GPCR ligand binding—CXCL10—Graves' disease	0.000266	0.00223	CbGpPWpGaD
Loperamide—POMC—Signaling by GPCR—IL2RA—Graves' disease	0.000263	0.00221	CbGpPWpGaD
Loperamide—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.000259	0.00217	CbGpPWpGaD
Loperamide—ABCB1—Allograft Rejection—HLA-DRB1—Graves' disease	0.000253	0.00212	CbGpPWpGaD
Loperamide—OPRK1—GPCR ligand binding—CXCL10—Graves' disease	0.000234	0.00196	CbGpPWpGaD
Loperamide—OPRD1—GPCR downstream signaling—TSHR—Graves' disease	0.000233	0.00195	CbGpPWpGaD
Loperamide—CALM3—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—Graves' disease	0.000227	0.0019	CbGpPWpGaD
Loperamide—CALM2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—Graves' disease	0.00022	0.00184	CbGpPWpGaD
Loperamide—CALM1—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—Graves' disease	0.00022	0.00184	CbGpPWpGaD
Loperamide—CALM3—Alzheimers Disease—IL1B—Graves' disease	0.000217	0.00182	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.000213	0.00179	CbGpPWpGaD
Loperamide—OPRD1—Signaling by GPCR—TSHR—Graves' disease	0.000211	0.00177	CbGpPWpGaD
Loperamide—CALM2—Alzheimers Disease—IL1B—Graves' disease	0.00021	0.00176	CbGpPWpGaD
Loperamide—CALM1—Alzheimers Disease—IL1B—Graves' disease	0.00021	0.00176	CbGpPWpGaD
Loperamide—CALM3—DAP12 interactions—HLA-B—Graves' disease	0.000206	0.00173	CbGpPWpGaD
Loperamide—OPRK1—GPCR downstream signaling—TSHR—Graves' disease	0.000204	0.00171	CbGpPWpGaD
Loperamide—CALM2—Cardiac Hypertrophic Response—TNF—Graves' disease	0.000204	0.00171	CbGpPWpGaD
Loperamide—CALM1—Cardiac Hypertrophic Response—TNF—Graves' disease	0.000204	0.00171	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—CXCL10—Graves' disease	0.000203	0.00171	CbGpPWpGaD
Loperamide—CALM2—DAP12 interactions—HLA-B—Graves' disease	0.0002	0.00167	CbGpPWpGaD
Loperamide—CALM1—DAP12 interactions—HLA-B—Graves' disease	0.0002	0.00167	CbGpPWpGaD
Loperamide—OPRM1—GPCR ligand binding—CXCL10—Graves' disease	0.000197	0.00165	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—TSHR—Graves' disease	0.000185	0.00155	CbGpPWpGaD
Loperamide—ABCB1—Allograft Rejection—IFNG—Graves' disease	0.000184	0.00155	CbGpPWpGaD
Loperamide—CALM3—Downstream signaling in naïve CD8+ T cells—TNF—Graves' disease	0.000182	0.00152	CbGpPWpGaD
Loperamide—CALM2—Downstream signaling in naïve CD8+ T cells—TNF—Graves' disease	0.000176	0.00148	CbGpPWpGaD
Loperamide—CALM1—Downstream signaling in naïve CD8+ T cells—TNF—Graves' disease	0.000176	0.00148	CbGpPWpGaD
Loperamide—OPRM1—GPCR downstream signaling—TSHR—Graves' disease	0.000173	0.00145	CbGpPWpGaD
Loperamide—ABCB1—Allograft Rejection—IL1B—Graves' disease	0.000165	0.00138	CbGpPWpGaD
Loperamide—ABCB1—Transmembrane transport of small molecules—GABRA3—Graves' disease	0.000164	0.00138	CbGpPWpGaD
Loperamide—CALM3—Platelet activation, signaling and aggregation—IL2RA—Graves' disease	0.000162	0.00136	CbGpPWpGaD
Loperamide—CALM3—Alzheimers Disease—TNF—Graves' disease	0.000158	0.00132	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—TSHR—Graves' disease	0.000157	0.00131	CbGpPWpGaD
Loperamide—CALM1—Platelet activation, signaling and aggregation—IL2RA—Graves' disease	0.000157	0.00131	CbGpPWpGaD
Loperamide—CALM2—Platelet activation, signaling and aggregation—IL2RA—Graves' disease	0.000157	0.00131	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—IL2RA—Graves' disease	0.000155	0.0013	CbGpPWpGaD
Loperamide—CALM2—Alzheimers Disease—TNF—Graves' disease	0.000152	0.00128	CbGpPWpGaD
Loperamide—CALM1—Alzheimers Disease—TNF—Graves' disease	0.000152	0.00128	CbGpPWpGaD
Loperamide—OPRD1—GPCR downstream signaling—CXCL10—Graves' disease	0.00015	0.00126	CbGpPWpGaD
Loperamide—CALM1—MicroRNAs in cardiomyocyte hypertrophy—TNF—Graves' disease	0.000145	0.00122	CbGpPWpGaD
Loperamide—CALM2—MicroRNAs in cardiomyocyte hypertrophy—TNF—Graves' disease	0.000145	0.00122	CbGpPWpGaD
Loperamide—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—Graves' disease	0.000144	0.00121	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—IFIH1—Graves' disease	0.000143	0.0012	CbGpPWpGaD
Loperamide—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—Graves' disease	0.000139	0.00116	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—IFIH1—Graves' disease	0.000138	0.00116	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—IFIH1—Graves' disease	0.000138	0.00116	CbGpPWpGaD
Loperamide—OPRD1—Signaling by GPCR—CXCL10—Graves' disease	0.000137	0.00115	CbGpPWpGaD
Loperamide—OPRK1—GPCR downstream signaling—CXCL10—Graves' disease	0.000132	0.00111	CbGpPWpGaD
Loperamide—CALM3—Myometrial Relaxation and Contraction Pathways—IL1B—Graves' disease	0.000127	0.00106	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—TSHR—Graves' disease	0.000125	0.00105	CbGpPWpGaD
Loperamide—CALM2—Myometrial Relaxation and Contraction Pathways—IL1B—Graves' disease	0.000122	0.00103	CbGpPWpGaD
Loperamide—CALM1—Myometrial Relaxation and Contraction Pathways—IL1B—Graves' disease	0.000122	0.00103	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—CXCL10—Graves' disease	0.00012	0.001	CbGpPWpGaD
Loperamide—ABCB1—Allograft Rejection—TNF—Graves' disease	0.000119	0.001	CbGpPWpGaD
Loperamide—OPRD1—GPCR downstream signaling—IL2RA—Graves' disease	0.000115	0.000964	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—HLA-E—Graves' disease	0.000113	0.000944	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—GC—Graves' disease	0.000112	0.00094	CbGpPWpGaD
Loperamide—OPRM1—GPCR downstream signaling—CXCL10—Graves' disease	0.000112	0.000935	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—TSHR—Graves' disease	0.00011	0.000919	CbGpPWpGaD
Loperamide—CALM3—Metabolism—GC—Graves' disease	0.000109	0.000915	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—HLA-E—Graves' disease	0.000109	0.000913	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—HLA-E—Graves' disease	0.000109	0.000913	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—HLA-E—Graves' disease	0.000108	0.000906	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—CD40—Graves' disease	0.000106	0.000886	CbGpPWpGaD
Loperamide—CALM2—Metabolism—GC—Graves' disease	0.000106	0.000885	CbGpPWpGaD
Loperamide—CALM1—Metabolism—GC—Graves' disease	0.000106	0.000885	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—HLA-E—Graves' disease	0.000105	0.000877	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—HLA-E—Graves' disease	0.000105	0.000877	CbGpPWpGaD
Loperamide—OPRD1—Signaling by GPCR—IL2RA—Graves' disease	0.000104	0.000876	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—CTLA4—Graves' disease	0.000104	0.000873	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—CD40—Graves' disease	0.000102	0.000857	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—CD40—Graves' disease	0.000102	0.000857	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—CXCL10—Graves' disease	0.000101	0.000849	CbGpPWpGaD
Loperamide—OPRK1—GPCR downstream signaling—IL2RA—Graves' disease	0.000101	0.000846	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—CTLA4—Graves' disease	0.000101	0.000845	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—CTLA4—Graves' disease	0.000101	0.000845	CbGpPWpGaD
Loperamide—CALM3—Disease—B3GNT2—Graves' disease	9.88e-05	0.000828	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—TSHR—Graves' disease	9.7e-05	0.000813	CbGpPWpGaD
Loperamide—CALM2—Disease—B3GNT2—Graves' disease	9.55e-05	0.000801	CbGpPWpGaD
Loperamide—CALM1—Disease—B3GNT2—Graves' disease	9.55e-05	0.000801	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—GC—Graves' disease	9.49e-05	0.000796	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—TSHR—Graves' disease	9.38e-05	0.000787	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—TSHR—Graves' disease	9.38e-05	0.000787	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—TSHR—Graves' disease	9.26e-05	0.000776	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—IL2RA—Graves' disease	9.16e-05	0.000768	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—HLA-DQB1—Graves' disease	8.58e-05	0.000719	CbGpPWpGaD
Loperamide—OPRM1—GPCR downstream signaling—IL2RA—Graves' disease	8.52e-05	0.000715	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—B3GNT2—Graves' disease	8.5e-05	0.000713	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—IL2RA—Graves' disease	8.35e-05	0.0007	CbGpPWpGaD
Loperamide—CALM3—Immune System—IFIH1—Graves' disease	8.33e-05	0.000699	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—HLA-DQB1—Graves' disease	8.3e-05	0.000696	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—HLA-DQB1—Graves' disease	8.3e-05	0.000696	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—GC—Graves' disease	8.27e-05	0.000694	CbGpPWpGaD
Loperamide—CALM3—Metabolism—B3GNT2—Graves' disease	8.27e-05	0.000694	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—IL2RA—Graves' disease	8.08e-05	0.000677	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—IL2RA—Graves' disease	8.08e-05	0.000677	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—CXCL10—Graves' disease	8.07e-05	0.000677	CbGpPWpGaD
Loperamide—CALM1—Immune System—IFIH1—Graves' disease	8.06e-05	0.000676	CbGpPWpGaD
Loperamide—CALM2—Immune System—IFIH1—Graves' disease	8.06e-05	0.000676	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—HLA-B—Graves' disease	8.02e-05	0.000673	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—CD8A—Graves' disease	8.01e-05	0.000671	CbGpPWpGaD
Loperamide—CALM1—Metabolism—B3GNT2—Graves' disease	8e-05	0.000671	CbGpPWpGaD
Loperamide—CALM2—Metabolism—B3GNT2—Graves' disease	8e-05	0.000671	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—GC—Graves' disease	7.79e-05	0.000654	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—HLA-B—Graves' disease	7.76e-05	0.000651	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—HLA-B—Graves' disease	7.76e-05	0.000651	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—CD8A—Graves' disease	7.75e-05	0.000649	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—CD8A—Graves' disease	7.75e-05	0.000649	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—IL2RA—Graves' disease	7.74e-05	0.000649	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—HLA-B—Graves' disease	7.7e-05	0.000646	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—HLA-B—Graves' disease	7.45e-05	0.000625	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—HLA-B—Graves' disease	7.45e-05	0.000625	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—B3GNT2—Graves' disease	7.2e-05	0.000603	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—HLA-A—Graves' disease	7.14e-05	0.000598	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—CXCL10—Graves' disease	7.08e-05	0.000594	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—HLA-A—Graves' disease	6.9e-05	0.000579	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—HLA-A—Graves' disease	6.9e-05	0.000579	CbGpPWpGaD
Loperamide—CALM3—Immune System—HLA-E—Graves' disease	6.56e-05	0.00055	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—HLA-DRB1—Graves' disease	6.52e-05	0.000547	CbGpPWpGaD
Loperamide—CALM3—Immune System—CD40—Graves' disease	6.41e-05	0.000537	CbGpPWpGaD
Loperamide—CALM1—Immune System—HLA-E—Graves' disease	6.34e-05	0.000532	CbGpPWpGaD
Loperamide—CALM2—Immune System—HLA-E—Graves' disease	6.34e-05	0.000532	CbGpPWpGaD
Loperamide—CALM3—Immune System—CTLA4—Graves' disease	6.32e-05	0.00053	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—HLA-DRB1—Graves' disease	6.31e-05	0.000529	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—HLA-DRB1—Graves' disease	6.31e-05	0.000529	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—CXCL10—Graves' disease	6.27e-05	0.000526	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—B3GNT2—Graves' disease	6.27e-05	0.000526	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—ICAM1—Graves' disease	6.26e-05	0.000525	CbGpPWpGaD
Loperamide—CALM2—Immune System—CD40—Graves' disease	6.2e-05	0.00052	CbGpPWpGaD
Loperamide—CALM1—Immune System—CD40—Graves' disease	6.2e-05	0.00052	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—IL2RA—Graves' disease	6.17e-05	0.000517	CbGpPWpGaD
Loperamide—CALM1—Immune System—CTLA4—Graves' disease	6.11e-05	0.000512	CbGpPWpGaD
Loperamide—CALM2—Immune System—CTLA4—Graves' disease	6.11e-05	0.000512	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—CXCL10—Graves' disease	6.06e-05	0.000508	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—CXCL10—Graves' disease	6.06e-05	0.000508	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—ICAM1—Graves' disease	6.05e-05	0.000508	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—ICAM1—Graves' disease	6.05e-05	0.000508	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—CXCL10—Graves' disease	5.98e-05	0.000502	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—B3GNT2—Graves' disease	5.91e-05	0.000495	CbGpPWpGaD
Loperamide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	5.89e-05	0.000494	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—TSHR—Graves' disease	5.73e-05	0.000481	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—TSHR—Graves' disease	5.54e-05	0.000465	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—TSHR—Graves' disease	5.54e-05	0.000465	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—IL2RA—Graves' disease	5.41e-05	0.000454	CbGpPWpGaD
Loperamide—CALM3—Immune System—HLA-DQB1—Graves' disease	5.2e-05	0.000436	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—GC—Graves' disease	5.1e-05	0.000427	CbGpPWpGaD
Loperamide—CALM1—Immune System—HLA-DQB1—Graves' disease	5.03e-05	0.000422	CbGpPWpGaD
Loperamide—CALM2—Immune System—HLA-DQB1—Graves' disease	5.03e-05	0.000422	CbGpPWpGaD
Loperamide—CALM3—Immune System—CD8A—Graves' disease	4.86e-05	0.000407	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—IL2RA—Graves' disease	4.79e-05	0.000402	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—CD4—Graves' disease	4.79e-05	0.000402	CbGpPWpGaD
Loperamide—CALM1—Immune System—CD8A—Graves' disease	4.7e-05	0.000394	CbGpPWpGaD
Loperamide—CALM2—Immune System—CD8A—Graves' disease	4.7e-05	0.000394	CbGpPWpGaD
Loperamide—CALM3—Immune System—HLA-B—Graves' disease	4.67e-05	0.000392	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—IL2RA—Graves' disease	4.64e-05	0.000389	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—IL2RA—Graves' disease	4.64e-05	0.000389	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—CD4—Graves' disease	4.63e-05	0.000388	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—CD4—Graves' disease	4.63e-05	0.000388	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—CD4—Graves' disease	4.6e-05	0.000386	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—IL2RA—Graves' disease	4.57e-05	0.000383	CbGpPWpGaD
Loperamide—CALM2—Immune System—HLA-B—Graves' disease	4.52e-05	0.000379	CbGpPWpGaD
Loperamide—CALM1—Immune System—HLA-B—Graves' disease	4.52e-05	0.000379	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—CD4—Graves' disease	4.45e-05	0.000373	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—CD4—Graves' disease	4.45e-05	0.000373	CbGpPWpGaD
Loperamide—CALM3—Immune System—IL2RA—Graves' disease	4.38e-05	0.000367	CbGpPWpGaD
Loperamide—CALM3—Immune System—HLA-A—Graves' disease	4.33e-05	0.000363	CbGpPWpGaD
Loperamide—CALM2—Immune System—IL2RA—Graves' disease	4.23e-05	0.000355	CbGpPWpGaD
Loperamide—CALM1—Immune System—IL2RA—Graves' disease	4.23e-05	0.000355	CbGpPWpGaD
Loperamide—CALM1—Immune System—HLA-A—Graves' disease	4.19e-05	0.000351	CbGpPWpGaD
Loperamide—CALM2—Immune System—HLA-A—Graves' disease	4.19e-05	0.000351	CbGpPWpGaD
Loperamide—CALM3—Disease—HLA-A—Graves' disease	4e-05	0.000335	CbGpPWpGaD
Loperamide—CALM3—Immune System—HLA-DRB1—Graves' disease	3.95e-05	0.000332	CbGpPWpGaD
Loperamide—CALM2—Disease—HLA-A—Graves' disease	3.87e-05	0.000324	CbGpPWpGaD
Loperamide—CALM1—Disease—HLA-A—Graves' disease	3.87e-05	0.000324	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—B3GNT2—Graves' disease	3.86e-05	0.000324	CbGpPWpGaD
Loperamide—CALM2—Immune System—HLA-DRB1—Graves' disease	3.83e-05	0.000321	CbGpPWpGaD
Loperamide—CALM1—Immune System—HLA-DRB1—Graves' disease	3.83e-05	0.000321	CbGpPWpGaD
Loperamide—CALM3—Immune System—ICAM1—Graves' disease	3.8e-05	0.000318	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CXCL10—Graves' disease	3.7e-05	0.000311	CbGpPWpGaD
Loperamide—CALM2—Immune System—ICAM1—Graves' disease	3.67e-05	0.000308	CbGpPWpGaD
Loperamide—CALM1—Immune System—ICAM1—Graves' disease	3.67e-05	0.000308	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CXCL10—Graves' disease	3.58e-05	0.0003	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CXCL10—Graves' disease	3.58e-05	0.0003	CbGpPWpGaD
Loperamide—CALM3—Immune System—IFNG—Graves' disease	2.89e-05	0.000242	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—IL2RA—Graves' disease	2.83e-05	0.000237	CbGpPWpGaD
Loperamide—CALM2—Immune System—IFNG—Graves' disease	2.79e-05	0.000234	CbGpPWpGaD
Loperamide—CALM1—Immune System—IFNG—Graves' disease	2.79e-05	0.000234	CbGpPWpGaD
Loperamide—CALM3—Immune System—CD4—Graves' disease	2.79e-05	0.000234	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—IL2RA—Graves' disease	2.74e-05	0.00023	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—IL2RA—Graves' disease	2.74e-05	0.00023	CbGpPWpGaD
Loperamide—CALM1—Immune System—CD4—Graves' disease	2.7e-05	0.000226	CbGpPWpGaD
Loperamide—CALM2—Immune System—CD4—Graves' disease	2.7e-05	0.000226	CbGpPWpGaD
Loperamide—CALM3—Immune System—IL1B—Graves' disease	2.58e-05	0.000216	CbGpPWpGaD
Loperamide—CALM3—Disease—CD4—Graves' disease	2.58e-05	0.000216	CbGpPWpGaD
Loperamide—CALM1—Immune System—IL1B—Graves' disease	2.49e-05	0.000209	CbGpPWpGaD
Loperamide—CALM2—Immune System—IL1B—Graves' disease	2.49e-05	0.000209	CbGpPWpGaD
Loperamide—CALM2—Disease—CD4—Graves' disease	2.49e-05	0.000209	CbGpPWpGaD
Loperamide—CALM1—Disease—CD4—Graves' disease	2.49e-05	0.000209	CbGpPWpGaD
